Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine (NQ: EDIT )

9.350 -0.220 (-2.30%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,931,705
Open 9.430
Bid (Size) 9.160 (3)
Ask (Size) 9.360 (1)
Prev. Close 9.570
Today's Range 9.020 - 9.530
52wk Range 7.705 - 21.59
Shares Outstanding 68,762,960
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
Why Shares of Editas Medicine Jumped This Week
It's been a seesaw month for the clinical-stage gene-editing biotech. 
Via The Motley Fool

Performance

YTD
+10.78%
+10.78%
1 Month
+5.41%
+5.41%
3 Month
-25.50%
-25.50%
6 Month
-40.97%
-40.97%
1 Year
-50.89%
-50.89%

More News

Read More
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
Via MarketBeat
Topics Workforce
Exposures Layoff Product Safety
Shoreline Biosciences Acquires Editas' iNK Cell Franchise, Related Gene Editing Technologies
Via Benzinga
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
From Editas Medicine, Inc.
Via Globe NewsWire
Analyst Expectations for Editas Medicine's Future
Via Benzinga
Why Editas Medicine Stock Is Sliding Today
Via The Motley Fool
Analyst Ratings for Editas Medicine
Via Benzinga
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
Via InvestorPlace
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
From Editas Medicine, Inc.
Via Globe NewsWire
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Editas Medicine, Inc.
Via Globe NewsWire
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
Via Benzinga
Why Shares of Editas Medicine Dropped 15.5% in November
Via The Motley Fool
Why Editas Medicine's Shares Are Falling Thursday
Via The Motley Fool
2 Beaten-Down Stocks to Watch Closely Next Year
Via The Motley Fool
Editas Medicine Touts Positive Safety, Efficacy Data From Two Sickle Cell Disease Patients
Via Benzinga
Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease
From Editas Medicine, Inc.
Via Globe NewsWire
Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
From Editas Medicine, Inc.
Via Globe NewsWire
Where Will Editas Medicine Be in 1 Year?
Via The Motley Fool
Gene Editing Stock's Prospects Cut In Half By Analyst, Citing Limited Value In Retina Treatment
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
Via Benzinga
Palo Alto To Surge Around 38%? Plus This Analyst Predicts $65 For Helmerich & Payne
Via Benzinga
Intuit To $490? Here Are 5 Other Price Target Changes For Friday
Via Benzinga
Gap To Rally 18%? Plus This Analyst Slashes PT On Super League Gaming By 50%
Via Benzinga
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.